Five Researchers Who Tried To Save Their Own Lives

Scientists, though striving for objectivity, are influenced by their personal experiences, which can profoundly shape their research. Sometimes, trauma or an unexpected diagnosis inspires them to investigate neglected or rare diseases. This personal connection, while seemingly biased, can be a powerful force for scientific advancement, as demonstrated by five scientists who found treatments for their own diagnoses. David Fajgenbaum, initially training to be a medical doctor, faced a rapid decline in his own health in 2010. His organs were failing, and he was diagnosed with idiopathic multicentric Castleman Disease, a rare and dangerous immune disorder. With no clear treatment, he used his medical training to investigate his condition. Analyzing his own blood samples from previous hospitalizations, he discovered that an enzyme called mTOR was in overdrive. This led him to identify sirolimus, an existing mTOR inhibitor, as a potential treatment. After convincing his physician to try the unapproved use of the drug, Fajgenbaum went into remission and remains so over a decade later. This success spurred him to establish a research lab dedicated to Castleman Disease, publishing findings that showed similar mTOR overexpression in other patients. His work has led to clinical trials for mTOR drugs in Castleman Disease and has advanced 14 existing drugs for repurposing to treat other rare diseases, saving thousands of lives, including his own. Chris Nowinski's career path took an unexpected turn after a severe concussion during his WWE wrestling career. The injury, which caused temporary amnesia, chronic headaches, and a sleep condition, inspired him to dedicate his life to studying head trauma. After writing a book on concussions in football and earning a PhD in behavioral neuroscience, Nowinski focused on chronic traumatic encephalopathy (CTE). Despite initial skepticism from medical examiners, he painstakingly collected brain samples from deceased head trauma victims. He established the Concussion and CTE Foundation, a brain bank, and a brain donation registry, which significantly increased data available for research. His work contributed to a 2024 study showing that CTE brains exhibit thinning and cell loss, similar to dementia, with severity linked to the duration of contact sports participation. Nowinski's advocacy has also led to rule changes in sports like American football, aiming to reduce head trauma. Sonia Vallabh, a law school graduate, drastically changed her career after her mother died from a genetic prion disease at age 51. An autopsy revealed the cause, and Vallabh discovered she carried the same fatal genetic mutation. With no cure, she and her husband pursued PhDs in biomedical science and opened a lab to study prion diseases. Their research focuses on reducing the rogue prion protein (PrP) before it misfolds and causes disease. Vallabh's unique perspective as an at-risk individual drives her search for preventative treatments. Her lab has shown in mice that even a 21% reduction in PrP can extend life and reverse some symptoms of prion disease. Clinical trials are underway, and Vallabh is optimistic about a treatment option for people like herself in the near future, emphasizing that knowledge from genetic testing can be empowering. Julio Saez-Rodriguez, a scientist researching the molecular basis of disease, was diagnosed with IgAN, a kidney disease he had never heard of, despite it causing a third of all adult kidney transplants. His diagnosis shifted his research focus from general bioinformatics to IgAN. He developed a tool to analyze large genetic datasets, identifying 20 molecules involved in IgAN, which could be targeted by existing drugs. This patient perspective also led him to create the IgAN atlas, a comprehensive database that compiles molecular data from multiple organs and patients to find more targeted treatments. The atlas has identified key cells, immune cell distributions, and a gene linked to IgAN inflammation, contributing to 24 ongoing clinical trials, one of which Saez-Rodriguez is participating in. Susan Michaelis, a commercial pilot, collapsed after a flight in 1997, an event that led her to investigate "aerotoxic syndrome." Her PhD research revealed that toxic fumes from jet engines, containing substances like carbon monoxide and organophosphates, can leak into plane cabins through "bleed air." This contamination, often unnoticed, can cause symptoms ranging from dizziness and fatigue to chronic organ damage. Michaelis's doctors believed these fumes caused her lobular breast cancer, a less common type that can evade standard screenings. Aircrew have higher rates of cancer, and Michaelis's work brought crucial attention to aerotoxic syndrome and lobular breast cancer before her death last year. Her efforts have spurred the airline industry to develop bleed-free engine designs and air quality sensors to prevent future incidents. These scientists, driven by personal health challenges, have not only sought to understand their own conditions but have also significantly advanced treatments and awareness for countless others facing similar illnesses, ultimately saving lives.